drugset / Trial / NCT00072670
A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
Phase 2
Completed
59 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PharmaMar · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety and efficacy of trabectedin (ET-743) in adult male participants with advanced metastatic (spread of cancer cells from one part of the body to another) prostate cancer.
Timeline
- Start
- 2004-01
- Primary completion
- 2008-09
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trabectedin | Small molecule | 0.58 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 1.2 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 1.5 mg/m2 | Intravenous |